VANCOUVER, British Columbia, Nov. 24, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TSX:TKM) (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today that the Company's President and Chief Executive Officer, Dr. Mark J. Murray, will present at the Piper Jaffray 22nd Annual Health Care Conference on Tuesday November 30, 2010 at 4:30 pm ET at the New York Palace Hotel in New York City. A webcast of the presentation will be available and can be accessed on the Company's website, www.tekmirapharm.com .
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com . Tekmira is based in Vancouver, B.C.The Tekmira Pharmaceuticals logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8319
CONTACT: The Equicom Group Investors Adam Peeler 416-815-0700 x 225 email@example.com Tekmira Pharmaceuticals Investors Ian Mortimer, Executive Vice President and Chief Financial Officer 604-419-3200 Longview Communications Inc. Media David Ryan 604-694-6031 firstname.lastname@example.org